OCGN

Ocugen, Inc.

Fundamental data last updated:August 22, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

 


Analyze OCGN on TradingView

VALUATION

P/E

-6.30

Market Cap ($M USD)

$477.32M

Forward P/E

0.84

PEG

0.00

PRICE TO SALES

106.90

PRICE TO BOOK

77.83

EV / EBITDA

-7.37

5-Year Average P/E

Free Cash Flow Yield

-12.48%

DCF Value

$-0.20

Graham Number

N/A

Price to FCF

-8.01

EV to FCF

-8.04

Earnings Yield

-15.86%

FCF Yield

-12.48%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.22

Next Year EPS Growth Estimate

$1.69

Next Year Revenue Growth Estimate

$1.21B

Return on Equity (ROE)

-127987.50%

FREE CASH FLOW

Operating Margin

-1483.85%

Debt-to-Equity

-2.72

Piotroski F-Score

2

Altman Z-Score

-8.64

Return on Invested Capital (ROIC)

-183.04%

Current Ratio

1.86

Quick Ratio

1.86

Net Debt to EBITDA

-0.02

Interest Coverage

-13.19

Gross Profit margin

100.00%

FCF PER SHARE

$-0.19

REVENUE PER SHARE

$0.01

Analyze OCGN on TradingView

Gainseekers Quantitative Analysis

Summary

The market’s perception of Ocugen, Inc. seems to be a rollercoaster of contradictions. Despite a Forward P/E of 0.83 suggesting potential undervaluation, the Altman Z-score of -7.90 screams financial distress. The negative Earnings Yield and a DCF Value far below the snapshot price indicate that the stock is trading at a premium relative to its intrinsic value. With a Price/Book ratio of 83.35, the market appears to be pricing in perfection, ignoring the glaring red flags in profitability and cash flow.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Ocugen is well-positioned to leverage AI and modern technological advancements. The industry’s reliance on cutting-edge research and development aligns with AI-driven innovations. This positioning could enhance their drug discovery processes and operational efficiencies.

The Bull Case

For the optimistic investor, Ocugen's Forward PEG ratio of 0.0009 is a beacon of hope, suggesting explosive growth potential relative to its price. The company's ability to project a massive sales growth next year could be a game-changer. Despite a low Piotroski F-Score, the potential for a turnaround in ROIC and the absence of debt-related stress provide a narrative of resilience and future profitability.

The Bear Case

However, the structural risks are daunting. With a Price/Sales ratio of 114.48 and a Price/Book ratio of 83.35, the stock is priced for perfection, leaving little room for error. The negative operating margin and ROIC highlight severe inefficiencies, while the Altman Z-score indicates a high risk of bankruptcy. The technical overextension near its 52-week high further exacerbates the risk for new investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$5.00

Institutional Ownership %

1-Year Beta

2.31

Insider Buying % (6 Mo)

Distance to 52-Week High

93.26%

Distance to 52-Week Low

43.26%

EARNINGS SURPRISE %

-20.00%

50-DAY SMA

$1.70

200-DAY SMA

$1.51

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.